1H-Pyrrolo[3,2,1-IJ]quinazoline | 56088-56-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 1H-Pyrrolo[3,2,1-IJ]quinazoline
• 英文别名: 1,10-diazatricyclo[6.3.1.04,12]dodeca-2,4(12),5,7,10-pentaene
• CAS: 56088-56-3
• 化学式: C₁₀H₈N₂
• 分子量: 156.18
• InChiKey: SPSIFDNPBXGZFG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  17.3
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• Preventives/remedies for urinary disturbance
  申请人：Ishihara Yuji

  公开号：US20050197362A1

  公开（公告）日：2005-09-08

  Preventives/remedies for voiding disturbance containing a compound having both of an acetylcholinesterase inhibitory action and an α1 antagonistic action which exhibits an excellent effect of improving the urinary function of the bladder (i.e., effects of improving urine flow rate and voiding efficiency) without affecting the urinary pressure or the blood pressure.

  具有乙酰胆碱酯酶抑制作用和α1拮抗作用的化合物的预防/治疗措施，可以显著改善膀胱的尿液功能（即改善尿流率和排尿效率的效果），而不影响尿压或血压。
• PREVENTIVES/REMEDIES FOR URINARY DISTURBANCE
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP1466625A1

  公开（公告）日：2004-10-13

  Preventives/remedies for voiding disturbance containing a compound having both of an acetylcholinesterase inhibitory action and an α1 antagonistic action which exhibits an excellent effect of improving the urinary function of the bladder (i.e., effects of improving urine flow rate and voiding efficiency) without affecting the urinary pressure or the blood pressure.

  预防/治疗排尿障碍的药物，其中含有一种同时具有乙酰胆碱酯酶抑制作用和α1拮抗作用的化合物，该化合物在不影响尿压或血压的情况下，对改善膀胱排尿功能（即改善尿流率和排尿效率）具有极佳的效果。
• PREVENTIVE/REMEDY FOR URINARY DISTURBANCE
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP1640021A1

  公开（公告）日：2006-03-29

  It is intended to provide a preventive/remedy for urinary disturbance containing a compound, which shows an acetylcholine esterase inhibitory activity but substantially has no butyrylcholine esterase inhibitory activity, showing no side effect and being safe and efficacious without inhibiting the urine collection function; a preventive/remedy for dry mouth induced by the administration of a remedy for urinary disturbance and a preventive or remedy for hyperactive bladder not accompanied by dry mouth; and a method of screening a substance preventing/treating urinary disturbance without inhibiting the urine collection function characterized by comprising measuring and comparing the acetylcholine esterase inhibitory activity and the butyrylcholine esterase inhibitory activity of a test compound.

  本发明旨在提供一种预防/治疗排尿障碍的药物，其中含有一种化合物，该化合物具有乙酰胆碱酯酶抑制活性，但基本上不具有丁酰胆碱酯酶抑制活性，且无副作用，安全有效，不会抑制尿液收集功能；一种预防/治疗因服用治疗排尿障碍的药物而引起的口干的药物，以及一种预防或治疗不伴有口干的膀胱过度活动症的药物；以及一种筛选预防/治疗排尿障碍而不抑制尿液收集功能的物质的方法，其特征在于包括测量和比较试验化合物的乙酰胆碱酯酶抑制活性和丁酰胆碱酯酶抑制活性。
• Soluble late transition metal catalysts for olefin oligomerizations III
  申请人：——

  公开号：US20040044150A1

  公开（公告）日：2004-03-04

  A series of soluble &agr;-diimine late transition metal catalysts has been invented comprising a substituted or unsubstituted catecholate ligand. The catalysts demonstrate high activity and selectivity for linear &agr;-olefins. As such, these catalysts conveniently oligomerize ethylene. Typical activators as known to those of ordinary skill in the art are used to activate these transition metal catalysts. These catalysts can be used in a supported or unsupported form.

  发明了一系列由取代或未取代的邻苯二酚配体组成的可溶性&agr;-二亚胺晚期过渡金属催化剂。这些催化剂对线性 &agr;-烯烃具有很高的活性和选择性。因此，这些催化剂可以方便地使乙烯低聚。本领域普通技术人员已知的典型活化剂可用于活化这些过渡金属催化剂。这些催化剂可以支撑或非支撑形式使用。
• Preventive/remedy for urinary disturbance
  申请人：Doi Takayuki

  公开号：US20070021391A1

  公开（公告）日：2007-01-25

  It is intended to provide a preventive/remedy for urinary disturbance containing a compound, which shows an acetylcholine esterase inhibitory activity but substantially has no butyrylcholine esterase inhibitory activity, showing no side effect and being safe and efficacious without inhibiting the urine collection function; a preventive/remedy for dry mouth induced by the administration of a remedy for urinary disturbance and a preventive or remedy for hyperactive bladder not accompanied by dry mouth; and a method of screening a substance preventing/treating urinary disturbance without inhibiting the urine collection function characterized by comprising measuring and comparing the acetylcholine esterase inhibitory activity and the butyrylcholine esterase inhibitory activity of a test compound.